Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 9,035 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pulmonary Clear all
Terminated Phase 2 Interventional Results available

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

NCT03366766
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Interventions
Nivolumab, Cisplatin, Pemetrexed Disodium, Gemcitabine Hydrochloride
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Abington, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Pilot Study)

NCT03865329
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Intervention- Home-based Pulmonary Rehabilitation
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 29, 2026, 5:30 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Centralized Screening Unit (CSU) at Montefiore-Einstein

NCT06284408
View directory record Official record
Conditions
Lung Cancer
Interventions
Centralized Screening Unit Implementation
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years to 77 Years
Enrollment
9,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
Drug
Lead sponsor
BlossomHill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

Multiparametric Image Analysis and Correlation With Outcomes in Lung Cancer Screening and Early Stage Lung Cancer

NCT03563976
View directory record Official record
Conditions
Lung Cancer
Interventions
Retrospective Study
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

NCT00888940
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
Ecallantide, Cyklokapron(R)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 29, 2026, 5:30 AM EDT
Completed No phase listed Observational

Remote Monitoring in Cancer Care: A Platform Study

NCT05018208
View directory record Official record
Conditions
Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Interventions
Computer-Assisted Intervention, Patient Monitoring, Questionnaire Administration
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 29, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

NCT05314517
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Namilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Readmission Reduction Interventions for Individuals With Sepsis or Pneumonia

NCT04829188
View directory record Official record
Conditions
Sepsis, Pneumonia, Lower Resp Tract Infection, Covid19
Interventions
Structured Telephone Support (STS), Low-intensity Remote Patient Monitoring (RPM-Low), High-intensity Remote Patient Monitoring (RPM-High), Standard Response Team, Enhanced Response Team
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Using Social Media to Decrease Healthcare Utilization for Pediatric Asthma

NCT05013788
View directory record Official record
Conditions
Asthma in Children
Interventions
Social Media Enhanced Education, Usual Asthma Education
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle

NCT03004586
View directory record Official record
Conditions
Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Lung Cancer
Interventions
25-Gauge Needle, 22-Gauge Needle, Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)
Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 29, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Elironrasib, Daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Duarte, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

NCT00519831
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, vinflunine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Is Osteopathic Manipulative Treatment (OMT) Beneficial for Elderly Patients Hospitalized With Pneumonia?

NCT00258661
View directory record Official record
Conditions
Pneumonia
Interventions
Osteopathic Manipulative Treatment, Light-touch Treatment
Procedure
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
50 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Mount Clemens, Michigan • Kirksville, Missouri • Stratford, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 29, 2026, 5:30 AM EDT
Recruiting Phase 4 Interventional

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

NCT07059494
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Y^90 Radioembolization
Drug · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Terminated Phase 4 Interventional Results available

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

NCT04381494
View directory record Official record
Conditions
Unresectable Stage III NSCLC
Interventions
Multiparametric Mobile Technology
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Long Beach, California • Santa Ana, California • Englewood, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

NCT05785845
View directory record Official record
Conditions
Early Stage Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions
Computed tomography-guided stereotactic adaptive radiotherapy, ETHOS
Radiation · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Not yet recruiting Early Phase 1 Interventional

BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

NCT07410312
View directory record Official record
Conditions
Lung Transplant Recipient
Interventions
Anakinra
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

NCT02228369
View directory record Official record
Conditions
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Interventions
AZD3759, AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 29, 2026, 5:30 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

NCT04386577
View directory record Official record
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 29, 2026, 5:30 AM EDT
Withdrawn Early Phase 1 Interventional

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

NCT02277457
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PET-Adaptive RT, Erlotinib, Crizotinib
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Connected Health to Increase Lung Cancer Screening

NCT04612946
View directory record Official record
Conditions
Lung Cancer
Interventions
Referral to Telemedicine LCS Counseling Visit, Usual Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 77 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Monitoring Metered Dose Inhalation (MDI) Volume and Timing With a Respimetrix Device in Obstructive Lung Disease.

NCT05495256
View directory record Official record
Conditions
Asthma, Copd
Interventions
Respimetrix
Device
Lead sponsor
Pulmonary Critical Care Associates of Baltimore
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 29, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer

NCT02606396
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
Cryotherapy, Esophagogastroduodenoscopy (EGD), Endoscopic ultrasound (EUS)
Procedure
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 29, 2026, 5:30 AM EDT